Table 2.

Patient Characteristics in Breast Cancer Cases and Controls

Note.—Unless otherwise noted, data are numbers of subjects, with percentages in parentheses. Thirty-eight (as opposed to 39) false-positive controls were included because there was one case for which no matched control could be identified.

^*Numbers in parentheses are age ranges.

^†Raloxifene (Evista) is manufactured by Eli Lilly and Company (Indianapolis, Ind); tamoxifen (Nolvadex) is manufactured by various companies.

^‡Risk factor for breast cancer determined at MR imaging screening. LCIS = lobular carcinoma in situ.

^§Remaining uninvolved and nontreated breast was examined at screening MR imaging.

^‖All lumpectomies were performed more than 5 years before the high-risk breast MR imaging screening examination.